



Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

June 1, 2016

[Download this Press Release](#)

Presentations to be Webcast on June 8, at 3:30 p.m. ET and June 21 at 9:00 a.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Jun. 1, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal company presentation, including a business overview and an update on Enanta's research and development pipeline at each of the following investor conferences:

- June 8, 3:30 p.m. ET – Jefferies 2016 Healthcare Conference, New York City
- June 21, 9:00 a.m. ET – JMP Securities Life Sciences Conference, New York City

A live webcast and replay of each presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at www.enanta.com. The replay webcast will be available following each presentation and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development efforts are currently focused on four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).

Enanta has discovered novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta's protease inhibitors, developed through its collaboration with AbbVie, include paritaprevir, which is contained in AbbVie's marketed DAA regimens for HCV, and ABT-493, Enanta's second protease inhibitor, which AbbVie is developing in phase 3 studies in combination with ABT-530, AbbVie's NS5A inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is now in phase 1 clinical development, and EDP-305, an FXR agonist, which Enanta plans to advance into clinical development for NASH later in 2016. Please visit www.enanta.com for more information on our programs and pipeline.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160601005316/en/>

Source: Enanta Pharmaceuticals, Inc.

Investor Contact

Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com